Avita Medical Ltd ((RCEL)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avita Medical Ltd (RCEL) is conducting a clinical study titled ‘A Prospective Post-Market Multicenter Randomized Controlled Clinical Study to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for the Management of Surgical Wounds.’ The study aims to compare the clinical outcomes and costs of using PermeaDerm versus frozen human cadaveric allograft (FHCA) as temporary dressings for surgical wounds requiring skin grafts. This research is significant as it could influence treatment protocols and healthcare costs associated with wound management.
The study tests two interventions: the PermeaDerm Biosynthetic Wound Matrix and Frozen Human Cadaveric Allograft (FHCA). Both are devices used as temporary dressings to prepare wounds for skin grafts, with the goal of improving wound healing and reducing complications.
This is a randomized, parallel-assignment study with no masking, primarily aimed at treatment. Patients are randomly assigned to receive either PermeaDerm or FHCA, and their outcomes are compared in terms of cost, wound healing, and safety.
The study began on February 21, 2025, with an expected primary completion date yet to be announced. The last update was submitted on June 27, 2025. These dates are crucial for tracking study progress and anticipating results.
The results of this study could impact Avita Medical’s stock performance by potentially increasing investor confidence if PermeaDerm proves cost-effective and clinically beneficial. This could also influence the competitive landscape in the wound care industry, where innovation is key.
The study is ongoing, with further details available on the ClinicalTrials portal.